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Achromobacter spp. are recognized as emerging pathogens in hospitalized as well as
in cystic fibrosis (CF) patients. From 2012 to 2015, we collected 69 clinical isolates
(41 patient) of Achromobacter spp. from 13 patients with CF (CF isolates, n = 32)
and 28 patients receiving care for other health conditions (non-CF isolates, n = 37).
Molecular epidemiology and virulence potential of isolates were examined. Antimicrobial
susceptibility, motility, ability to form biofilms and binding affinity to mucin, collagen,
and fibronectin were tested to assess their virulence traits. The nrdA gene sequencing
showed that A. xylosoxidans was the most prevalent species in both CF and non-CF
patients. CF patients were also colonized with A. dolens/A. ruhlandii, A. insuavis, and
A. spiritinus strains while non-CF group was somewhat less heterogenous, although A.
insuavis, A. insolitus, and A. piechaudii strains were detected beside A. xylosoxidans.
Three strains displayed clonal distribution, one among patients from the CF group and
two among non-CF patients. No significant differences in susceptibility to antimicrobials
were observed between CF and non-CF patients. About one third of the isolates were
classified as strong biofilm producers, and the proportion of CF and non-CF isolates with
the ability to form biofilm was almost identical. CF isolates were less motile compared
to the non-CF group and no correlation was found between swimming phenotype
and biofilm formation. On the other hand, CF isolates exhibited higher affinity to bind
mucin, collagen, and fibronectin. In generall, CF isolates from our study exhibited in vitro
properties that could be of importance for the colonization of CF patients.
Keywords: cystic fibrosis, Achromobacter spp., nrdA, antimicrobial resistance, virulence traits
INTRODUCTION
Achromobacter spp. are recognized as emerging pathogens that can cause infections in patients with
impaired immune system and are well-known nosocomial pathogens, especially in the intensive
care units (ICUs). Also, Achromobacter spp. have been increasingly isolated from respiratory
secretions of individuals with cystic fibrosis (CF), in which genetic disorder causes accumulation of
thick sticky mucus, mostly in the lungs, leading to frequent bacterial pulmonary infections (Ronne
Hansen et al., 2006; Amoureux et al., 2013).
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A. xylosoxidans is the predominantly isolated Achromobacter
species from the CF clinical samples. The prevalence of
A. xylosoxidans in CF patients ranges from 2% to up to 21.8% as
reported by a Brazilian CF center (Tan et al., 2002; Pereira et al.,
2011); other authors reported an increase in prevalence as well
(Emerson et al., 2010; Ridderberg et al., 2011). The frequency of
A. xylosoxidans isolation in some European centers is relatively
high, e.g., 16% in an Italian CF center (Trancassini et al., 2014)
and 17.5% in a CF center in France (Amoureux et al., 2013).
Apart from increased prevalence, A. xylosoxidans clinical
isolates demonstrated broad-spectrum multiple drug resistance,
though not uniformly. Intrinsic and acquired resistance tend to
limit the choice of antibiotics that can be successfully used in the
treatment of infections caused by this bacterium.
Other Achromobacter species, namely A. ruhlandii, A.
piechaudii, A. denitrificans, A. spanius, A. insolitus and A.
marplatensis have been less frequently associated with CF lung
disease comparing to A. xylosoxidans (Coenye et al., 2003;
Gomila et al., 2011). However, as epidemiology, clinical impact
and antibiotic resistance patterns of these novel Achromobacter
species in CF patients are still unknown, they are the subject of
the expanding interest.
Despite their more frequent isolation and ever-emerging
multidrug-resistant strains, little is known regarding the
virulence characteristics of Achromobacter. The mechanisms
that make Achromobacter species able to adhere, colonize
and subsequently infect the respiratory tract are still unclear.
Therefore, investigation of the organization and expression of
virulence factors is important, particularly as the incidence of
Achromobacter infections continues to rise.
Over the past few years, Achromobacter spp. have been
recovered with increasing frequency at the Mother and
Child Health Care Institute of Serbia “Dr Vukan Cˇupic´,” a
400-bed university-affiliated pediatric tertiary care hospital
in Belgrade, Serbia. The National Cystic Fibrosis Center
located within the hospital complex provides multidisciplinary
care to outpatients and inpatients of all ages. During the
two-and-a-half-year period (from November 2012 to March
2015), we prospectively collected 69 clinical Achromobacter
spp. isolates from patients with CF (CF isolates) and
patients receiving care for other health conditions (non-CF
isolates).
The aims of this study were to unveil the molecular
epidemiology and the virulence potential of the Achromobacter
spp. of CF and non-CF origin in a large Serbian clinical setting.
MATERIALS AND METHODS
Patients
During the study period (November 2012 to March 2015),
Achromobacter spp. were recovered from clinical samples
obtained from 41 patients (18 males and 23 females, male:female
ratio 1:1.25). Among them, 13 were CF patients treated as
outpatients and inpatients (the average age was 7.5 years, range
0–30 years). Out of 28 patients treated for health disorders not
related to CF (non-CF group, average age 4.4 years, range 0–
17 years), 20 (71.4%) were hospitalized in two ICUs (pediatric
medical and surgical ICU), while the remaining 8 were treated
on different specialized clinical wards.
Bacterial Strains
69 Achromobacter spp. clinical isolates were collected. Thirty-
two CF isolates were cultured from sputum (n = 19), cough
swabs (n = 7), bronchoalveolar lavage fluid (BALF) (n = 3)
and blood (n = 3) (Table 1). In total, 24 isolates were recovered
from chronically colonized patients (6 patients) and 8 isolates
were recovered from transient colonization (7 patients) (Table 1).
Chronic colonization was defined as at least three positive
cultures per year, with a minimum 1-month interval between
them, for at least 2 years (Pereira et al., 2011). Thirty-seven
non-CF isolates were cultured from a number of sites, including
tracheal aspirate (n = 25), BALF (n = 4), sputum (n = 4), blood
(n= 2), nasal swab (n= 1), and ear swab (n= 1) (Table 2). These
strains were collected from colonized non-CF patients, and in
majority of them the prolonged carriage was noted.
At least one isolate per patient was included, as well
as subsequent isolates that were considered phenotypically
different. The strains’ names were assigned randomly to preserve
the anonymity of the patients. The study protocol was approved
by Ethical Comittee of the Mother and Child Health Care
Institute “Dr Vukan Cupic,” (approval No. 8/6).
Identification and Phylogenetic Analyses
Preliminary identification of isolates was performed by the Vitek
2 automated system (bioMérieux, Marcy l′Etoile, France) and
sequencing of genes for 16S rRNA; PCR amplification of the 16S
rRNA gene was performed using primers UNI 16SF (5–GAG
AGT TTG ATC CTG GC-3) and UNI 16SR (5-AGG AGG TGA
TCC AGC CG-3) (Jovcic et al., 2009). Species identification was
performed by sequencing of nrdA gene as described previously
(Spilker et al., 2012). The PCR products were purified by using
the GeneJET PCR Purification Kit (Thermo Scientific, Lithuania)
and sequenced by the MACROGEN service (Macrogen Inc.,
Netherlands). For 16S rRNA identification Basic Local Alignment
Search Tool (BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi) was
used for searches against GenBank database. The phylogenetic
inferences between Achromobacter spp. were obtained by MEGA
version 6.0 (Tamura et al., 2013). The nrdA gene sequences
were trimmed to 449 bp and aligned using Clustal W with
default parameters. The construction of a phylogenetic tree was
conducted by the maximum-likelihood (ML) method using a
Tamura-Nei model. Data for the 28 reference strains were derived
from pubMLST website (http://pubmlst.org/achromobacter/)
and included in this analysis. Bootstrapping of 1,000 replicates
was used to infer confidence levels of ML trees. The nrdA
gene sequences from analyzed strains are deposited in GenBank
BankIt2010541: KY968572–KY968640.
Pulsed Field Gel Electrophoresis (PFGE)
Genetic relatedness among analyzed isolates was determined by
PFGE analysis of XbaI digested genomic DNA. Electrophoresis
was carried out for 18 h using contour-clamped homogeneous
electric field system (2015 Pulsafor unit; LKB Pharmacia,
Sweden) in 0.5X TBE (45 mmol/l Tris base, 45mmol/l boric
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acid, and 1mmol/l EDTA pH 8), as described previously (Barton
et al., 1995). A dendrogram was derived from the Ward linkage
of correlation coefficients between PFGE patterns of different
genotypes by using SPSS cluster analysis software (IBM Corp.
Released 2012. IBM SPSS Statistics for Windows, Version 21.0.
Armonk, NY: IBM Corp.). Tenover’s criteria were used for the
interpretation of PFGE results (Tenover et al., 1995).
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing was performed by the
disk diffusion method according to recommendations of
Clinical and Laboratory Standards Institute (CLSI, 2014).
Isolates were tested against 10 antimicrobial agents: ceftazidime
(30µg), ceftriaxone (30µg), aztreonam (30µg), imipenem
(10µg), amikacin (30µg), gentamicin (10µg), ciprofloxacin
(5µg), levofloxacin (5µg), tetracycline (30µg), chloramphenicol
(30µg) (BioRad, France). For antibiotics with undefined
breakpoints for Achromobacter spp. in current standards,
breakpoints for Pseudomonas aeruginosa were used.
Minimal inhibitory concentrations (MICs) were determinated
by microdilution testing following CLSI breakpoints for other
non-Enterobacteriaceae. Susceptibility was tested against
imipenem (4–16µg/ml), meropenem (4–16µg/ml), piperacillin
(16–128µg/ml), piperacillin/tazobactam (16/4–128/4µg/ml),
tetracycline (4–16µg/ml) and trimethoprim/sulfamethoxazole
(2/38–4/76µg/ml) for all isolates, while only isolates displaying
intermediate susceptibility or resistance with the disk diffusion
method were tested against ceftazidime (8–32µg/ml),
ciprofloxacin (1–4µg/ml), levofloxacin (2–8µg/ml) and
chloramphenicol (8–32µg/ml). Experiments were done in
triplicate. After 24 h incubation at 37◦C, cell density was
monitored by OD600 measurements in a microtiter Plate Reader
Infinite 200 pro (MTX Lab Systems, Austria), and MIC values
were determinated as the lowest concentration of antibiotic that
inhibited bacterial growth.
Detection of ESBL and MBL Producing
Isolates
The double disc synergy test (DDST) was used to screen
for extended-spectrum beta-lactamase (ESBL)-producing strains.
Isolates presumed to be ESBL producers on the basis of screening
test results were subjected to the phenotypic confirmatory test
(Tsering et al., 2009). Only the ones positive in the confirmatory
test were analyzed by molecular testing methods.
The detection of metallo-beta-lactamase (MBL) producers
was carried out by disc diffusion test with imipenem (10µg) and
imipenem/EDTA (10µg/930µg) (Yong et al., 2002).
The PCR method was used for detection of genes encoding
various beta-lactamases (ESBL, AmpC-like, MBL) in selected
candidates. Sets of primers specific for the TEM, SHV, CTX-
M, OXA-1, OXA-2, OXA-114, CMY-1, CMY-2, VEB-1, DHA-1,
GES-7, IMP-1, IMP-2, VIM-2, NDM-1, TMB, and SIM genes
used in this study are listed in Table 3.
Biofilm Formation
Biofilm formation assay was performed according to the method
described previously (Stepanovic´ et al., 2007), withmodifications.
Wells of 96-well microtiter plates (Tissue Culture Plate, Sarstedt,
Germany) were filled with 180µl Luria-Bertani broth medium
and then 20µl aliquotes of overnight cultures of Achromobacter
spp. strains (adjusted to the 0.5 McFarland standard) were added.
All strains were tested in triplicate. Sterile medium tested in
triplicate was used as negative control. Microtiter plates were
incubated aerobically for 48 h at 37◦C. After incubation and
washing (three times with phosphate-buffered saline, PBS; pH
7.2) remaining bacteria were fixed by drying at 65◦C for 30
min. For staining and visualization of biofilm, 0.1% crystal violet
(HiMedia Labs Pvt. Ltd., India) was used (30 min at room
temperature). The stain was rinsed by washing three times with
1X PBS and then resolubilised with 96% ethanol and acetone
(4:1). Quantification of biofilm formation was done bymeasuring
absorbance at 595 nm using Plate Reader Infinite 200 pro (MTX
Lab Systems, Austria).
On the basis of biofilm formation,Achromobacter spp. isolates
were divided into four classes: no biofilm producer (N), weak
(W), moderate (M), and strong (S) biofilm producer (Stepanovic´
et al., 2007).
Motility Assay
Swimming assay of Achromobacter strains was performed on
plates containing tryptone (10 g/l), NaCl (5 g/l), and 0.3%
(wt/vol) agarose (Trancassini et al., 2014). Plates were inoculated
with one colony of each strain and incubated at 37◦C for
18 h. For defining the motility of a specific strain, the diameter
of the resulting concentric ring, expressed in millimeters, was
measured. If growth diameter could not be measured isolates
were classified as non-motile.
Mucin Adhesion Ability
The binding of bacterial cells to mucin was tested according
to the method described previously (Muñoz-Provencio et al.,
2009), with modifications. The wells of microtiter plates (Tissue
Culture Plate, Sarstedt, Germany) were coated at 4◦C for 24 h
with 200µl of porcine stomach mucin type II (Sigma, Germany).
The main component of porcine stomach mucin is MUC2,
which is homologous to human MUC5AC mucin produced by
superficial epithelium in trachea and bronchi (Turner et al.,
2007; Kreda et al., 2012). Mucin was resuspended in 50mM
carbonate buffer (pH 9.6; 30mg/ml) and the same volume of
carbonate buffer was added to the control wells (without mucin).
All wells were washed three times with 1X PBS. Afterwards,
PBS with 1% Tween 20 was added to saturate the uncoated
binding places. After 1 h incubation at room temperature, the
wells were washed once more with 1X PBS and, subsequently,
200µl of each bacterial suspension in 1X PBS was added (the
suspension was adjusted to 0.5 McFarland standard). Bacterial
suspensions were prepared by resuspension of overnight cultures
in PBS. Each strain was tested in triplicate in both coated and
control wells. After incubation for 2 h at 37◦C, the wells were
washed three times with 1X PBS containing 0.05% Tween 20
to remove nonadherent cells. Fixation of mucin-bound bacterial
cells was performed by drying the plate at 65◦C for 45min.
Subsequently, 200µl aliquots of crystal violet (HiMedia Labs
Pvt. Ltd., India) were added to the wells in a final concentration
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TABLE 3 | List of primers used in this study.
Primers Gene Sequence 5′ →3′ Th (◦C) References
VEB-1F blaVEB−1 CCAGATAGGAGTACAGAC 47
◦C Neuwirth et al., 2006
VEB-1R GACTCTGCAACAAATACGC
SHVF blaSHV GTCAGCGAAAAACACCTTGCC 47
◦C Sharma et al., 2013
SHVR GTCTTATCGGCGATAAACCAG
CMY-1F blaCMY−1 GCTGCTCAAGGAGCACAGGATCCCG 61
◦C Teo et al., 2012
CMY-1R GGCACATTGACATAGGTGTGGTGCATG
CMY-2F blaCMY−2 ACTGGCCAGAACTGACAGGCAAA 57
◦C Teo et al., 2012
CMY-2R GTTTTCTCCTGAACGTGGCTGGC
CTX-MF blaCTX−M GAAGGTCATCAAGAAGGTGCG 48
◦C Sharma et al., 2013
CTX-MR GCATTGCCACGCTTTTCATAG
DHA-1F blaDHA−1 GTCGCGGCGGTGGTGGAC 57
◦C Teo et al., 2012
DHA-1R CCGCACCCAGCACACCTGT
TEMF blaTEM ATAAAATTCTTGAAGACGAAA 52
◦C Teo et al., 2012
TEMR GACAGTTACCAATGCTTAATCA
GES-7F blaGES−7 ATCTTGAGAAGCTAGAGCGCG 48
◦C Teo et al., 2012
GES-7R GTTTCCGATCAGCCACCTCT
OXA-1F blaOXA−1 CTTGATTGAAGGGTTGGGCG 55
◦C Aubert et al., 2001
OXA-1R AGCCGTTAAAATTAAGCCC
OXA-2F blaOXA−2 GAAGAAAACGCTACTCGC 47
◦C Orman et al., 2002
OXA-2R TACCCACCAACCCATAC
OXA-114A blaOXA−114 ACGCCTGAACCCTTTTATCC 50
◦C Amoureux et al., 2013
OXA-114B ATCGACAGGCCGCGCAGT
IMP-1F blaIMP−1 TGAGCAAGTTATCTGTATTC 48.5
◦C Yan et al., 2001
IMP-1R TTAGTTGCTTGGTTTTGATG
IMP-2F blaIMP−2 GGCAGTCGCCCTAAAACAAA 45
◦C Yan et al., 2001
IMP-2R TAGTTACTTGGCTGTGATGG
VIM-2F4 blaVIM−2 GTTTGGTCGCATATCGCA 51
◦C Ellington et al., 2007
VIM-2R4 AATGCGCAGCACCAGGAT
NDMfullF blaNDM−1 TCAGCGCAGCTTGTCGGCC 58
◦C Teo et al., 2012
NDMfullR ATGGAATTGCCCAATATTATG
Trip75 blaTMB−1 ACCCGGATTGGAAGTTGAGG 54
◦C El Salabi et al., 2012
Trip617R TTCTAGCGGATTGTGGCCAC
SIMF blaSIM TACAAGGGATTCGGCATC 52
◦C Ellington et al., 2007
SIMR TAATGGCCTGTTCCCATG
of 0.1mg/ml. After 45min, the solution was decanted and the
unbound stain was removed by three washes with 1X PBS,
and finally citrate buffer (50mM; pH 4) was added to dissolve
the stain bound to the bacterial cells. After 1 h incubation at
room temperature, the absorbance wasmeasured at 595 nm using
the Labsystems Multiskan RC plate reader (MTX Lab Systems,
Austria).
Collagen-and Fibronectin-Binding Assay
The wells of Maxisorb plates (Nunc, Roskilde, Denmark) were
coated with type I collagen (from rat tail, BD Bioscience, New
Jersey, United States) (100µg/ml) or human fibronectin (Serva,
Heidelberg, Germany) (100µg/ml) for 16 h at 4◦C. The collagen-
binding ability of the selected strains was tested according to
Miljkovic et al. (2015), while their ability to bind fibronectin
was assayed as previously described by Ahmed et al. (2001).
After immobilization, the wells were washed with PBS and
blocked with 2% BSA in PBS. When the BSA solution was
removed, the wells were washed with PBS and the test cultures
(100µl, 108 CFU/ml) were added. Plates were incubated on
an orbital platform shaker for 3 h at 37◦C. Then, nonadherent
cells were removed by washing the wells three times with
200µl of PBS. The adherent cells were fixed at 60◦C for
20min and stained with crystal violet (100µl/well, 0.1% solution)
for 45min. Wells were subsequently washed three times with
PBS to remove the excess stain. The stain bound to the cells
was dissolved in 100µl of citrate buffer (pH 4.3) and the
absorbance was measured at 595 nm after 45min using the
microtiter plate reader. Results were expressed as the mean of
six replicates relative to those of the same non-coated wells.
Laboratory strain Lactococcus lactis BGKP1 was used as a positive
control.
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Elastase Assay
Supernatants of overnight cultures were mixed with phosphate
buffer (0.1 M, pH 6.3) in a 2:1 ratio. Elastin-Congo red (Sigma,
St. Louis, United States) was added to the final concentration of
2 mg/ml and the mixtures were incubated at 37◦C with shaking
(200 rpm) for 1 week and subsequently centrifuged at 10,000
× g for 10 min. The absorbance was measured at 495 nm
and the values were subtracted from a blank containing NaCl
(0.9%) incubated without supernatant (Jakobsen et al., 2013).
Pseudomonas aeruginosa PAO1 was used as a positive control.
Summarising the Virulence Properties Data
In order to summarize virulence potential data for the analyzed
strains heat map was constructed using Rx64 3.2.3. software.
A dendrogram was created by clustering algorithm that
related rows by similarity. The results were approximated on
the relative scale ranging from 0 (blue) as the lowest values,
progressing to white, then to 100 (red) as the highest values.
Analyzed strains were separated into three clusters which
summarize each virulence factor potential.
Statistical Analysis
For comparing differences in biofilm formation,motility, mucin-,
collagen-, and fibronectin-adhesion ability between CF and non-
CF isolates, Mann-Whitney test was used. Correlations between
tested parameters were performed using Spearman’s test. Results
are represented as box-plots. To compare the proportion of
motile strains between CF and non-CF patients, Pearson’s chi-
squared test was used. All statistical analyses and drawing of
graphs and dendrograms for PFGE analysis were performed in
SPSS 21.0 for Windows.
RESULTS
Achromobacter spp. Isolates and nrdA
Gene Sequence Clustering
Identification by the Vitek 2 system and 16S rRNA genes
sequencing revealed that all 69 isolated strains belonged to
Achromobacter spp. Species-level identification performed by
the nrdA gene sequencing showed that A. xylosoxidans was the
most prevalent species (60/69, 87.0%). The nrdA gene sequence
clustering successfully segregated 60 isolates of A. xylosoxidans
into 4 defined clusters (Figure 1). Achromobacter species other
than A. xylosoxidans were identified as A. dolens/ A. ruhlandii
(5657B, 5657C, MS4, and MS9 CF isolates, 4/69, 5.8%, these
species were undistinguishable with used the nrdA gene
sequences), A. insuavis (1874 CF and 6651 non-CF isolate, 2/69,
2.9%), A. spiritinus (10448 CF isolate, 1/69, 1.4%), A. insolitus
(A5 non-CF isolate, 1/69, 1.4%) and A. piechaudii (7491 non-CF
isolate, 1/69, 1.4%) (Figure 1).
Genotype Analysis by PFGE
According to the obtained PFGE XbaI fingerprint, a dendrogram
was constructed for all isolates and shown in Figure 2. The PFGE
analysis revealed considerable genetic heterogeneity between
strains within both CF and non-CF group, as well as between
groups. The CF isolates were genetically more heterogeneous
FIGURE 1 | Maximum-likelihood phylogenetic tree based on definite
article the nrdA gene sequences (449 bp alignment) of Achromobacter
type strains. Data for reference strains were derived from the
pubMLST website (http://pubmlst.org/achromobacter/). Type strains of
species represented amnong strains from the study are highlighted.
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FIGURE 2 | Dendrogram created according to PFGE profile of XbaI
digested genomic DNA of CF (red) and non-CF (black) Achromobacter
spp. isolates.
comparing to the non-CF group. However, three clusters
of epidemiologically related isolates were detected. Possible
nosocomial transmission was detected between two CF patients
carrying A. xylosoxidans strains 3F and 10412 with the same
genotype according to PFGE (Figure 2); both patients were
treated in the CF unit a couple of months apart. Secondly,
three non-CF patients treated at the medical ICU were colonized
with A. xylosoxidans strains 11462, 651/14, and 320FA sharing
identical banding patterns (Figure 2). Finally, A. xylosoxidans
strains A2 and A3, isolated from two non-CF patients treated
at the medical ICU, were indistinguishable as shown by PFGE
(Figure 2).
Antimicrobial Susceptibility Testing
All 69 isolates were tested for susceptibility to 10 antimicrobial
agents by the disk diffusion method. The results showed high
overall frequency of resistance to aztreonam 88.4% (27/32,
84.4% CF isolates and 34/37, 91.9% non-CF isolates), gentamicin
87.0% (28/32, 87.5% CF isolates and 32/37, 86.5% non-CF
isolates), tetracycline 84.1% (26/32, 81.3% CF isolates and
32/37, 86.5% non-CF isolates), amikacin 73.9% (22/32, 68.8%
CF isolates and 29/37, 78.4% non-CF isolates) and ceftriaxone
68.1% (22/32, 68.8% CF isolates and 25/37, 67.6% non-CF
isolates). Overall resistance to imipenem, chloramphenicol,
levofloxacin, ciprofloxacin and ceftazidime was not significant
(less than 20%) (Figure 3). A. dolens/A. ruhlandii isolates
showed multiresistant patterns according to the disc diffusion
method. Strains MS4 and MS9 were resistant to most of
the tested antibiotics except levofloxacin, ciprofloxacin and
ceftazidime (MS4), and levofloxacin, ciprofloxacin, imipenem,
and chloramphenicol (MS9), while 5657B and 5657C isolates
were resistant to tetracycline, aztreonam, gentamicin, amikacin,
and ceftriaxone. A. insuavis isolates were resistant to imipenem
and amikacin (CF isolate marked as 1874) and aztreonam,
gentamicin, ceftriaxone (non-CF isolate marked as 6651). A.
spiritinus isolate was resistant only to gentamicin, A. insolitus to
aztreonam, while A. piechaudii isolate was sensitive to all tested
antibiotics.
According to the results obtained by microdilution test,
88.4% (61/69) of isolates were resistant to tetracycline,
thereof 81.3% (26/32) CF isolates, and 94.6% (35/37) non-
CF isolates. There were 46.4% (32/69) of isolates resistant to
trimethoprim/sulfamethoxazole, 28.1% (9/32) CF isolates, and
62.2% (23/37) non-CF isolates. 23.2% (16/69) were resistant
to imipenem, 28.1% (9/32) CF isolates and 18.9% (7/37)
non-CF isolates. Percentage of isolates resistant to piperacillin
was 18.8% (13/69), 15.6% (5/32) CF isolates, and 21.6%
(8/37) non-CF isolates, while 15.9% (11/69) were resistant to
piperacillin/tazobactam, 15.6% (5/32) CF isolates and 16.2%
(6/37) non-CF isolates. 5.8% (4/69) were resistant to meropenem,
all of them belonging to the CF group. Percentages of resistant
CF and non-CF isolates are presented in Figure 4.
Determination of MIC values for antibiotics used in
disk diffusion method was performed only for resistant and
intermediate strains. Obtained results revealed that 15.9% (11/69)
isolates were resistant to chloramphenicol, 9.4% (3/32) CF
isolates and 21.6% non-CF isolates. 11.6% (8/69) were resistant
to ciprofloxacin, 18.7% (6/32) CF isolates and 5.4% (2/37) non-
CF isolates. Only 4.3% (3/69) were resistant to levofloxacin, 9.4%
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FIGURE 3 | Distribution of antibiotic resistances among CF and non-CF Achromobacter spp. isolates determined by disk diffusion method. TET,
tetracycline; IPM, imipenem; ATM, aztreonam; CHL, chloramphenicol; LVX, levofloxacin; CIP, ciprofloxacin; GMN, gentamicin; CRO, ceftriaxone; AKN,
amikacin; CAZ, ceftazidime; S, sensitive; I, intermediate; R, resistant.
FIGURE 4 | Distribution of antibiotic resistances among CF and non-CF Achromobacter spp. isolates determined by microdilution method. TET,
tetracycline; IPM, imipenem; MEM, meropenem; CHL, chloramphenicol; LVX, levofloxacin; CIP, ciprofloxacin; PIP, piperacillin; TZP,
piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole; CAZ, ceftazidime; NT, not tested; S, sensitive; I, intermediate; R, resistant.
(3/32) CF isolates; and 2.9% (2/69) isolates were resistant to
ceftazidime 6.2% (2/32) of CF isolates (Figure 4).
A. dolens/A. ruhlandii isolates showed multiresistant
phenotype according to the microdilution test, except
5657B isolate which was resistant only to tetracycline and
trimethoprim/sulfamethoxazole. A. insuavis 1874 isolate was
resistant to imipenem and trimethoprim/sulfamethoxazole. A.
spiritinus, A. piechaudii, and non-CF isolate A. insuavis 6651
were sensitive to all tested antibiotics.
ESBL and MBL Activity
DDST assay and phenotypic confirmatory test revealed that
56.3% (18/32) CF and 48.6% (18/37) non-CF isolates were
putatively ESBL positive. Imipenem and imipenem/EDTA test
revealed presence of 28.1% (9/32) CF and 43.2% (16/37) non-CF
isolates as putative MBL-producers. A. insolitus and A. dolens/A.
ruhlandii (5657B, 5657C, and MS9) isolates were phenotypically
MBL-positive. 12.5% (4/32) CF and 16.2% (6/37) non-CF isolates
were both ESBL andMBL positive.A. dolens/A. ruhlandiiMS4,A.
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insuavis, A. spiritinus and A. piechaudii were detected as neither
ESBL nor MBL-producers. Isolates selected by phenotypic tests
were analyzed for the presence of common ESBL or MBL genetic
determinants. Two non-CF isolates (A3 and A4) were confirmed
for the presence of blaCMY−2 gene which encodes AmpC beta-
lactamase, a clinically important cephalosporinase.
Biofilm Formation
Under the tested conditions, only two CF isolates (A. spiritinus
10448 and A. dolens/A. ruhlandii MS9) out of 69 tested (2/69,
2.9%) were unable to produce biofilm (N class). 23.2% (16/69)
isolates were classified as weak (W) biofilm producers, thereof
18.8% (6/32) from CF and 27.0% (10/37) from non-CF group.
44.9% (31/69) isolates were moderate (M) biofilm producers;
of those, 46.9% (15/32) were CF isolates, and 43.2% (16/37)
non-CF isolates. 29.0% (20/69) isolates were strong (S) biofilm
producers, 28.1% (9/32) of them were CF isolates, and 29.7%
(11/37) non-CF.
A. insuavis, A. piechaudii, and A. dolens/A. ruhlandii 5657B
were classified as weak (W) biofilm producers. A. insolitus and A.
dolens/A. ruhlandii 5657C were moderate (M) biofilm producers,
while A. dolens/A. ruhlandii MS4 was a strong (S) biofilm
producer.
No statistical differences were observed in biofilm formation
between the CF and non-CF group of isolates.
Motility Assay
Motility of the isolates was tested by a swimming motility assay
and the results were expressed as the diameter of growth ring
in millimeters (data not shown). It was established that 82.61%
(57/69) were positive for swimming motility, thereof 71.87%
(23/32) from the CF group and 91.89% (34/37) from the non-
CF group. Only A. insuavis 6651 was positive for swimming
motility among the non-xylosoxidans Achromobacter isolates.
To compare the proportion of motile strains between CF and
non-CF patients, the Pearson’s chi-square test was used [p(χ2)
= 0.029]. Different levels of motility between bacteria isolated
from CF and non-CF patients are presented in Figure 5. Strains
isolated from the non-CF patients showed a higher degree of
motility relative to the CF strains, according to the Mann-
Whitney test (p= 0.044) (Figure 5).
Mucin-, Collagen-, and
Fibronectin-Adhesion Ability and Elastase
Activity
Collagen-, fibronectin-, and mucin-binding ability (expressed
relatively to control non-coated wells in the microtiter plate) of
bacterial isolates are shown in Figure 6. Strains derived from
the CF patients exhibited higher binding affinity to collagen and
mucin compared to the non-CF strains (p < 0.05, according to
the Mann-Whitney test), while for fibronectin binding, only a
statistical trend (p < 0.1) was observed (Figure 6). Among the
non-xylosoxidans Achromobacter species, A. spiritinus showed
the highest binding affinity to collagen, whileA. insuavis 1874 had
the highest binding affinity to fibronectin. None of the isolates
showed elastase activity.
FIGURE 5 | Motility of CF isolates relative to non-CF isolates; # denotes
statistical significance relative to non-CF isolates.
Comparative Evaluation of Achromobacter
spp. Virulence
A heat map demonstrating distribution of the virulence
characteristics analyzed in this study was constructed in order
to summarize the overall virulence potential of CF and non-CF
isolates (Figure 7). According to the heat map, all tested isolates
can be divided into three distinct clusters: CF group (cluster I),
non-CF group (cluster II), and the cluster III comprising the
strains considered to be the most virulent, including 7 CF and
3 non-CF isolates (Figure 7).
DISCUSSION
Epidemiology, antibiotic resistance and virulence traits of 69
Achromobacter spp. isolates recovered from clinical samples
were analyzed in this study. A. xylosoxidans was the most
prevalent species among the strains of both CF (81.3%) and
non-CF origin (91.9%). This finding is in correlation with
data reported in other studies (Ridderberg et al., 2012; Perez-
Losada et al., 2013; Spilker et al., 2013). The CF patients
followed at the National CF Center of Serbia were also
colonized with A. dolens/A. ruhlandii, A. insuavis, and A.
spiritinus strains, while the non-CF group of isolates was
somewhat less heterogeneous with A. insuavis, A. insolitus,
and A. piechaudii strains detected beside A. xylosoxidans.
A. ruhlandii has been reported as the second most common
species in CF patients, with a very high prevalence rate
(23.5%) in the USA and only 3% in the UK (Spilker et al.,
2013; Coward et al., 2015). Nevertheless, the epidemiology
and possible clinical significance of non-xylosoxidans
Achromobacter species in CF and non-CF patients are generally
unknown.
The genotypic analysis by PFGE revealed considerable genetic
heterogeneity, indicating that most of the patients harbored
their own unique strains. A marked diversity of Achromobacter
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FIGURE 6 | Collagen (A), fibronectin (B), and mucin (C) binding abilities of CF and non-CF isolates; ◦ and * represent extreme and outlier values,
respectively; # denotes statistical significance relative to non-CF isolates.
FIGURE 7 | Heat map demonstrating the distribution of virulence traits in CF- and non-CF Achromobacter isolates. Results were approximated on the
relative scale ranging from 0 (blue) as the lowest values, progressing to white, then to 100 (red) as the highest values.
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spp. genotypes was also detected in other CF centers (Pereira
et al., 2011; Amoureux et al., 2013), suggesting that the
majority of the isolates probably originate from environmental
sources.
However, in our study, three A. xylosoxidans strains were
involved in instances of possible clonal distribution; one was
shared between two CF patients treated in the CF unit a
couple months apart, and the other two were isolated from
non-CF patients treated at the medical ICU. Although rare,
cross-transmission of A. xylosoxidans has been detected in
some CF centers (Van Daele et al., 2005; Pereira et al., 2011).
There are limited data available on the cross-transmission
capacity of non-xylosoxidans Achromobacter strains, except
those concerning the spread of a particular clone of A.
ruhlandii among CF patients in Denmark (Hansen et al.,
2013).
Colonization of the CF lung by multiresistant Achromobacter
strains, primarily A. xylosoxidans, has proved to be a treatment
challenge. The data on resistance profiles and underlying
resistance mechanisms of other Achromobacter spp. are very
limited. Resistance phenotypes for aztreonam, gentamicin and
amikacin were similar to data obtained in an Italian CF
center (Trancassini et al., 2014), and weren’t surprising due
to A. xylosoxidans intrinsic resistance to aminoglycosides and
aztreonam (Rolston and Messer, 1990; Almuzara et al., 2010).
Although A. xylosoxidans bears innate resistance
to aminoglycosides, literature data suggest that some
Achromobacter spp. strains are susceptible to these drugs
(Bador et al., 2016). This is in accordance with our study and
could explain detected susceptibility to aminoglycosides among
studied isolates.
Since disk diffusion method is not validated by the CLSI
nor EUCAST for most of the nonfermenting Gram-negative
bacilli antibiotic susceptibility was additionaly tested by
microdilution method. Results obtained by the disk diffusion
correlated to those from microdilution method for some of
the tested antibiotics (chloramphenicol, levofloxacin, and
ceftazidime). About one half of tested isolates were resistant
to trimethoprim/sulfamethoxazole, which is often used for
treating infections caused by A. xylosoxidans. Piperacillin,
piperacillin/tazobactam, and carbapenems displayed the
best antibacterial effect against the tested strains, as was the
case in some of the other studies (Almuzara et al., 2010).
Meropenem had higher efficiency in comparison to imipenem,
confirming its status of most effective carbapenem (Almuzara
et al., 2010). Among non-xylosoxidans Achromobacter strains,
A. dolens/A. ruhlandii showed a multiresistant phenotype.
Low specifity and positive predictive value of conventional
phenotypic method for detecting MBL producers revealed
in our study had previously been described for other
Gram-negative non-fermenting bacilli (Samuelsen et al.,
2008).
Despite the increasing importance of Achromobacter spp.
little is known about the virulence factors associated with these
bacteria. So, this study aimed to explore and analyze the virulence
armament of Achromobacter clinical strains through expression
of characteristics such as biofilm formation, motility, production
of elastase and adhesion capacity to collagen, fibronectin and
mucin. These bacterial features are generally considered to be
important for in vivo colonization and infection (Brogden et al.,
2007). The ability to form biofilms contributes significantly to
increased bacterial resistance to antimicrobials and antiseptics,
resulting in treatment failure and persistance of infection. Among
the tested isolates, about one third were classified as strong
biofilm producers, including A. dolens/A. ruhlandii MS4 strain
that was the only non-xylosoxidans Achromobacter species from
the study in this group. The ability ofAchromobacter spp. to form
biofilms was demonstrated earlier (Jakobsen et al., 2013), and in
some CF centers as many as half of the tested strains were strong
biofilm producers (Trancassini et al., 2014).
Given the described correlation between the loss of swimming
motility and pathogenesis of CF lung infections, we assessed
the presence of this trait in our isolate collection. CF isolates
from this study were less motile, in tested conditions, compared
to non-CF isolates. We could assume that diminished motility
among our CF isolates might serve as an competitive advantage
in establishing an infection in the airways, as was shown for
some other Gram-negative non-fermenting bacilli of CF origin
(Wolfgang et al., 2004). No correlation was found between
swimming phenotype and biofilm formation, which has also been
shown in the study from an Italian CF center (Trancassini et al.,
2014).
Mucus hyperproduction in the airways is one of the hallmarks
of the chronic airway diseases, including CF. To the best of our
knowledge, this study is the first to examine the mucin binding
ability of Achromobacter spp. Higher afinity of CF isolates to
mucin compared to non-CF isolates was not surprising and
might be the result of adaptive responses to mucus accumulation
in the lungs of CF patients. Additionally, binding ability of CF
isolates to collagen was significantly higher comparing to non-CF
isolates, while for fibronectin binding only a statistical trend (p<
0.1) was observed. Higher affinity of CF isolates was expected as
in CF lungs deposition of collagen and fibronectin is increased
(Wilson and Wynn, 2009).
Unraveling of virulence traits indicated that ten isolates stood
out from the rest in terms of analzyed phenotypes (cluster
III, Figure 7), including A. xylosoxidans, A. dolens/A. ruhlandii,
A. spiritinus, and A. insuavis strains. In addition, A. dolens/A.
ruhlandii strains showed multiresistant patterns. The isolates
belonging to the cluster III had a higher binding affinity for
collagen and fibronectin as well as strong biofilm formation
properties, while motility of most strains in this group was very
low or they were non-motile, in general.
In summary, this study analyzed epidemiology, drug
resistance and virulence potential of Achromobacter species
collected from CF and non-CF patients receiving care in a
large tertiary care pediatric hospital in Serbia. A. xylosoxidans
was the most common species retrieved, but several non-
xylosoxidans Achromobacter spp. were also included in the
study, which might enhance the rather limited exhisting
data on various features of this species. The isolates of CF
origin were less motile, but exhibited higher binding affinity
to mucin, collagen and trend for higher binding affinity to
fibronectin.
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